Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/18/2019 |
| Start Date: | January 2005 |
| End Date: | February 2015 |
Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer
This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer
cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a
proposed biological treatment of patients with end-stage, treatment-resistant cancer. The
macrobeads have been extensively tested in tumor models in mice and rats, as well as in
forty-five veterinary patients (cats and dogs) with naturally occurring tumors of various
types including breast cancer, prostate cancer, liver cancer, and lymphoma with clear tumor
responses and no significant detectable toxicity.
cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a
proposed biological treatment of patients with end-stage, treatment-resistant cancer. The
macrobeads have been extensively tested in tumor models in mice and rats, as well as in
forty-five veterinary patients (cats and dogs) with naturally occurring tumors of various
types including breast cancer, prostate cancer, liver cancer, and lymphoma with clear tumor
responses and no significant detectable toxicity.
Cancer in its various forms continues to be a major U.S. health problem, accounting for
550,000 deaths a year, as well as much disability and suffering. Treatment for cancer has
traditionally consisted of three modalities: surgery, radiation therapy, and chemotherapy.
Advances with all three modalities over the years have produced long-term remissions and/or
cures in certain types of cancer such as the leukemias, and prolonged survival for many other
patients. Much remains to be accomplished, however, especially with respect to the treatment
of solid tumors, including some of the most common cancers such as those of the lung, colon,
breast, ovary, prostate and kidney. New types of less toxic and debilitating therapy are
needed.
Among the therapeutic possibilities currently being explored, those that involve biological
control mechanisms seem both promising and attractive. Although it has long been thought that
cancer cells are not subject to the same regulatory growth control mechanisms that function
in normal cells, there is a substantial body of evidence that they can respond to feedback
signals telling them to slow or stop their growth. In addition, it has been determined that a
relatively small population of cells within a tumor (cancer "stem" or progenitor cells) are
responsible for continued tumor growth and that it is these cells that must be controlled if
biological anti-tumor therapy is to be effective.
The proposed cancer treatment being tested in this Phase 1 clinical trial is based on the
concept that tumor growth can be controlled by tumor mass or signals that indicate that such
mass is present. In this case, however, the induction of the growth-slowing signals is
brought about not by tumor mass, but by placing mouse kidney cancer cells in an agarose
matrix, which both selects for cancer progenitor cells and also causes them to produce and
release signals that inhibit the growth of freely growing cancer cells of the same or
different type in a laboratory dish or in a tumor-bearing animal or human (i.e. is also not
species-specific). This approach has proven both safe and effective in animal models and
veterinary patients, and it is now in the first stage of human testing. With Phase 1
completed, we are now implementing Phase 2 efficacy trials that for the present are focused
on colorectal cancer, pancreatic cancer, and prostate cancer. The Phase 1 trial remains open
to a range of epithelial-derived cancer.
550,000 deaths a year, as well as much disability and suffering. Treatment for cancer has
traditionally consisted of three modalities: surgery, radiation therapy, and chemotherapy.
Advances with all three modalities over the years have produced long-term remissions and/or
cures in certain types of cancer such as the leukemias, and prolonged survival for many other
patients. Much remains to be accomplished, however, especially with respect to the treatment
of solid tumors, including some of the most common cancers such as those of the lung, colon,
breast, ovary, prostate and kidney. New types of less toxic and debilitating therapy are
needed.
Among the therapeutic possibilities currently being explored, those that involve biological
control mechanisms seem both promising and attractive. Although it has long been thought that
cancer cells are not subject to the same regulatory growth control mechanisms that function
in normal cells, there is a substantial body of evidence that they can respond to feedback
signals telling them to slow or stop their growth. In addition, it has been determined that a
relatively small population of cells within a tumor (cancer "stem" or progenitor cells) are
responsible for continued tumor growth and that it is these cells that must be controlled if
biological anti-tumor therapy is to be effective.
The proposed cancer treatment being tested in this Phase 1 clinical trial is based on the
concept that tumor growth can be controlled by tumor mass or signals that indicate that such
mass is present. In this case, however, the induction of the growth-slowing signals is
brought about not by tumor mass, but by placing mouse kidney cancer cells in an agarose
matrix, which both selects for cancer progenitor cells and also causes them to produce and
release signals that inhibit the growth of freely growing cancer cells of the same or
different type in a laboratory dish or in a tumor-bearing animal or human (i.e. is also not
species-specific). This approach has proven both safe and effective in animal models and
veterinary patients, and it is now in the first stage of human testing. With Phase 1
completed, we are now implementing Phase 2 efficacy trials that for the present are focused
on colorectal cancer, pancreatic cancer, and prostate cancer. The Phase 1 trial remains open
to a range of epithelial-derived cancer.
Inclusion Criteria:
- End-stage, treatment resistant epithelial-derived cancer (carcinoma) arising
originally within the abdominal cavity with expected minimum six-month survival
Exclusion Criteria:
- Multiple intraabdominal metastases or carcinomatosis or other medical conditions
indicating that the procedure would be of too high a risk for the individual
We found this trial at
1
site
Click here to add this to my saved trials
